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Results: PRS interacts with ELCs on case-control status, in the three inde-
pendent samples from USA (p= p=0.004), Italy (p=0.018) and Germany 
(p=0.018); in each sample the variance of schizophrenia explained by PRS 
is multiplicatively higher in the presence of a history of ELCs compared 
with the absence of such events. The relationship between genomic risk and 
ELCs is further replicated in the two independent samples of only cases 
from Germany (p=0.047) and Japan (p=0.044). The gene-set based on PRS 
loci interacting with ELCs is highly expressed in multiple placental tissues 
(p<0.001) and dynamically regulated in placental samples from compli-
cated, in comparison with normal, pregnancies (p<0.05). These differences 
are significantly greater in placentae from male compared with female off-
spring (p<10–8). The interaction between PRS and ELCs is largely driven 
by PlacPRS genes (p=0.002); PRS constructed from the remaining loci do 
not interact with ELCs (NonPlacPRS, p=0.60). Pathways and biological 
functions associated with NonPlacPRS genes are reminiscent of previous 
analyses about schizophrenia risk-genes, while PlacPRS genes implicate an 
orthogonal biology, with roots in the fetal/placental response to hypoxic 
stress.
Discussion: Our data suggest that the most significant schizophrenia GWAS 
variants contribute to risk at least partly by converging on a developmental 
trajectory sensitive to ELCs and altered placental gene expression. The sex-
associated effects on placental transcription suggest that the male prepon-
derance of schizophrenia may arise from gene-environment interactions 
that influence placental biology. These results highlight placental health as 
a new public health frontier for primary prevention, particularly in high-
risk males.
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Background: 22q11.2 Deletion Syndrome (22q11.2DS) is caused by the dele-
tion of approximately 60 genes on chromosome 22 and represents one of 
the strongest known genetic risk factors for schizophrenia. Approximately 
1 in 4 adults with 22q11.2DS are diagnosed with schizophrenia spectrum 
disorders, presenting with psychotic symptomatology analogous to that 
exhibited in idiopathic schizophrenia.
Cognitive deficits are a core feature of schizophrenia. 22q11.2DS presents 
a valuable model for understanding vulnerable periods of cognitive devel-
opment which may be associated with psychosis development. Most pre-
vious studies report greater deficits in older individuals with 22q11.2DS 
than younger individuals but these studies have often focused solely on IQ, 
neglecting other neurocognitive domains associated with schizophrenia. 
Additionally, many studies of 22q11.2DS have not included adults, missing 
a crucial group at increased risk for schizophrenia. The first aim was there-
fore to examine whether there are increasing deficits in cognitive function-
ing on a wide range of domains in 22q11.2DS across developmental stages 
(children, adolescents and adults) compared to typically developing (TD) 
controls. The second aim was to take into account the presence of a psy-
chotic disorder, and whether this explained variance in functioning.
Methods: We conducted the largest study to date of neurocognitive func-
tioning beyond IQ in 22q11.2DS. This work was the result of international 
collaboration across 3 sites. The same battery of tasks measuring process-
ing speed, attention and spatial working memory were completed by 219 
participants with 22q11.2DS and 107 TD controls. Wechsler IQ tests were 
completed, yielding Full Scale (FSIQ), Verbal (VIQ) and Performance 
IQ scores (PIQ). An age-standardised difference score was produced for 
each participant taking into account TD control performance. The average 
performance of children (6–10 years), adolescents (10–18 years) and adults 
(18–56 years) was compared using an ANOVA approach. No children or 
adolescents reached diagnostic criteria for a psychotic disorder, but 13% 
of adults with 22q11.2DS were either diagnosed with a DSM-IV psychotic 
disorder. The cognitive performance of adults with or without a psychotic 
disorder was compared with independent t-tests with correction for une-
qual variance.
Results: Children and adults with 22q11.2DS displayed a greater defi-
cit in working memory than adolescents (p=0.017 and p<0.001 respec-
tively). Adults displayed greater deficits in FSIQ and PIQ than adolescents 
(p=0.018 and p=0.001 respectively). Adults diagnosed with a psychotic 
disorder displayed a greater deficit in VIQ than those without a psychotic 
disorder (p=0.040).
Discussion: Magnitude of cognitive deficit in individuals with 22q11.2DS 
varied by cognitive domain and developmental stage. There were specific 
deficits in working memory, PIQ and FSIQ in adults with 22q11.2DS com-
pared to children and adolescents. The lack of differences between children 
and adolescents contradicts previous research which proposes that older 
children exhibit greater cognitive deficits, and suggests that there may be 
a longer developmental window to intervene and maintain cognitive func-
tioning in a group at high genomic risk of schizophrenia. Adults with 
22q11.2DS and psychotic disorder had a greater deficit in VIQ, which sup-
ports previous research. This international sample provides unique insights 
into cognitive functioning in 22q11.2DS across developmental stages.
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Background: Patients with schizophrenia have a high mortality risk. The 
role of clozapine in the long-term mortality risk is insufficiently known. 
The objectives of the current study were to determine in i) all-cause long-
term mortality rates and ii) specific-cause mortality rates and ratios in 
patients with schizophrenia with and without clozapine treatment.
Methods: We systematically searched EMBASE, MEDLINE and 
PsycINFO and included studies that used a long-term follow-up design 
(i.e., ≥52 weeks) and reported on mortality in adults diagnosed with schizo-
phrenia-spectrum disorders receiving clozapine treatment.
Results: Altogether, 23 studies fulfilled our criteria, reporting on 1,166 deaths 
during 203,231 patient years for patients treated with clozapine. Pooling 
five cohort studies that included sufficient sample sizes and length of fol-
low-up, we found an unadjusted mortality rate of 7.34 per 1,000 patient 
years (95%CI=4.39–10.28). Long-term, crude mortality rate ratios were 
significantly lower in patients treated with clozapine compared to patients 
without clozapine treatment (mortality rate ratio=0.59, 95%CI=0.43–0.81, 
p-value<0.001) as well as compared to other antipsychotic medications 
(mortality rate ratio=0.61, 95%CI=0.45–0.84, p-value=0.002). We found 
incomplete and inconsistent reporting of specific-cause mortality rates. 
Statistical heterogeneity was high in all analyses.
Discussion: Future studies with substantial length of follow-up and uni-
form reporting of confounders are needed to validate these findings of a 
significantly lower mortality risk in patients using clozapine, in particular 
for the risk of cardiovascular mortality.
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